Target expression details
| Target's General Information | |||||
|---|---|---|---|---|---|
| Target ID | T00140 | ||||
| Target Name | Arachidonate 5-lipoxygenase (5-LOX) | ||||
| Synonyms | LOG5; 5-lipoxygenase; 5-LO | ||||
| Target Type | Successful | ||||
| Gene Name | ALOX5 | ||||
| Biochemical Class | Oxygenase | ||||
| UniProt ID | LOX5_HUMAN | ||||
| Target's Expression Profile in Disease Related Tissue between Patients and Normal People | |||||
| Disease | Atopic dermatitis | ||||
| Example drug | ETH615 | Discontinued in Phase 2 | [1], [2], [3] | ||
| Tissue | Skin | ||||
| Level of differential expression between the patients in the disease section of the tissue and the tissues of healthy individual |
Fold-change: -0.22 Z-score: -0.78 P-value: 2.96E-03 |
||||
|
Target gene expression profiles of the patients in the disease section of the tissue
Target gene expression profiles in the tissue of healthy individual
|
|||||
| Disease | Chronic obstructive pulmonary disease | ||||
| Example drug | MLN-977 | Discontinued in Phase 2 | [2], [3], [4] | ||
| Tissue | Lung tissue | ||||
| Level of differential expression between the patients in the disease section of the tissue and the tissues of healthy individual |
Fold-change: -0.18 Z-score: -0.25 P-value: 7.42E-01 |
||||
|
Target gene expression profiles of the patients in the disease section of the tissue
Target gene expression profiles in the tissue of healthy individual
|
|||||
| Disease | Chronic obstructive pulmonary disease | ||||
| Example drug | MLN-977 | Discontinued in Phase 2 | [2], [3], [4] | ||
| Tissue | Small airway epithelium | ||||
| Level of differential expression between the patients in the disease section of the tissue and the tissues of healthy individual |
Fold-change: 0.43 Z-score: 0.63 P-value: 1.25E-03 |
||||
|
Target gene expression profiles of the patients in the disease section of the tissue
Target gene expression profiles in the tissue of healthy individual
|
|||||
| Disease | Osteoarthritis | ||||
| Example drug | Licofelone | Discontinued in Phase 1 | [2], [3], [5] | ||
| Tissue | Synovial tissue | ||||
| Level of differential expression between the patients in the disease section of the tissue and the tissues of healthy individual |
Fold-change: -0.26 Z-score: -0.47 P-value: 3.25E-01 |
||||
|
Target gene expression profiles of the patients in the disease section of the tissue
Target gene expression profiles in the tissue of healthy individual
|
|||||
| Disease | Asthma | ||||
| Example drug | ABT-761 | Phase 3 | [2], [3], [6] | ||
| Tissue | Nasal and bronchial airway | ||||
| Level of differential expression between the patients in the disease section of the tissue and the tissues of healthy individual |
Fold-change: 0.14 Z-score: 0.28 P-value: 9.43E-03 |
||||
|
Target gene expression profiles of the patients in the disease section of the tissue
Target gene expression profiles in the tissue of healthy individual
|
|||||
| Disease | Rheumatoid arthritis | ||||
| Example drug | Flobufen | Phase 3 | [2], [3], [7] | ||
| Tissue | Synovial tissue | ||||
| Level of differential expression between the patients in the disease section of the tissue and the tissues of healthy individual |
Fold-change: 0.55 Z-score: 2.11 P-value: 1.00E-02 |
||||
|
Target gene expression profiles of the patients in the disease section of the tissue
Target gene expression profiles in the tissue of healthy individual
|
|||||
| Disease | Psoriasis | ||||
| Example drug | CMI-392 | Phase 2 | [2], [3], [8] | ||
| Tissue | Skin | ||||
| Level of differential expression between the patients in the disease section of the tissue and the tissues of healthy individual |
Fold-change: -4.92E-03 Z-score: -0.01 P-value: 5.19E-01 |
||||
| Level of differential expression between the patients in the disease section of the tissue section of the tissue adjacent to the disease section |
Fold-change: 0.36 Z-score: 1.51 P-value: 3.46E-15 |
||||
|
Target gene expression profiles of the patients in the disease section of the tissue
Target gene expression profiles of the patients in the normal section of the tissue adjacent to the disease section
Target gene expression profiles in the tissue of healthy individual
|
|||||
| Disease | Arteriosclerosis | ||||
| Example drug | PD-146176 | Terminated | [2], [3], [9] | ||
| Tissue | Peripheral blood | ||||
| Level of differential expression between the patients in the disease section of the tissue and the tissues of healthy individual |
Fold-change: -0.11 Z-score: -0.24 P-value: 4.99E-01 |
||||
|
Target gene expression profiles of the patients in the disease section of the tissue
Target gene expression profiles in the tissue of healthy individual
|
|||||
| Disease | Prostate cancer | ||||
| Tissue | Prostate | ||||
| Level of differential expression between the patients in the disease section of the tissue and the tissues of healthy individual |
Fold-change: -0.06 Z-score: -0.15 P-value: 4.15E-01 |
||||
|
Target gene expression profiles of the patients in the disease section of the tissue
Target gene expression profiles in the tissue of healthy individual
|
|||||
| Disease | Sensitive skin | ||||
| Tissue | Skin | ||||
| Level of differential expression between the patients in the disease section of the tissue and the tissues of healthy individual |
Fold-change: 0.08 Z-score: 0.38 P-value: 8.61E-01 |
||||
|
Target gene expression profiles of the patients in the disease section of the tissue
Target gene expression profiles in the tissue of healthy individual
|
|||||
| Target's Expression Profile across Various Tissues of Healthy Individual | |||||
|
|||||
| References | |||||
| REF 1 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800006733) | ||||
| REF 2 | Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. | ||||
| REF 3 | NCBI GEO: archive for functional genomics data sets--update. Nucleic Acids Res. 2013 Jan;41(Database issue):D991-5. | ||||
| REF 4 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800007577) | ||||
| REF 5 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800003927) | ||||
| REF 6 | ABT-761 (Abbott). Curr Opin Investig Drugs. 2001 Jan;2(1):68-71. | ||||
| REF 7 | Pharmacological profile of the novel potent antirheumatic 4-(2',4'-difluorobiphenyl-4-yl)-2-methyl-4-oxobutanoic acid. Arzneimittelforschung. 1997 May;47(5):648-52. | ||||
| REF 8 | Anti-inflammatory activities of LDP-392, a dual PAF receptor antagonist and 5-lipoxygenase inhibitor. Pharmacol Res. 2001 Sep;44(3):213-20. | ||||
| REF 9 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800010267) | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.